Skip to main content
OpenTrials

Clinical trial condition

HER2/Neu Negative

Explore clinical trials studying HER2/Neu Negative. Study availability and eligibility vary by location and protocol.

55 public trials 3 recruiting studies
Refine in advanced search Browse all conditions

HER2/Neu Negative trial results

Recruiting

S1703 Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer

NCT03723928

Conditions
Anatomic Stage IV Breast Cancer AJCC v8, Elevated CA15-3 or CEA or CA27-29, Estrogen Receptor Positive, +3 more
Locations
  • Anchorage Associates in Radiation Medicine Anchorage, Alaska, United States
  • Anchorage Radiation Therapy Center Anchorage, Alaska, United States
  • Alaska Breast Care and Surgery LLC Anchorage, Alaska, United States
  • Alaska Oncology and Hematology LLC Anchorage, Alaska, United States
View all 723 locations
View Trial Details
Recruiting

Multicenter Trial for Eliminating Breast Cancer Surgery or Radiotherapy in Exceptional Responders to Neoadjuvant Systemic Therapy

NCT02945579

Conditions
Breast Diseases, Breast Neoplasms, Estrogen Receptor Negative, +16 more
Locations
  • MD Anderson Cancer Center - Banner Gilbert, Arizona, United States
  • Baptist MD Anderson Cancer Center Jacksonville, Florida, United States
  • Queen's Medical Center Honolulu, Hawaii, United States
  • Mayo Clinic Rochester, Minnesota, United States
View Trial Details
Completed

Paclitaxel & Cyclophosphamide With or Without Trastuzumab Before Surgery in Treating Previously Untreated Breast Cancer

NCT01750073

Conditions
Breast Diseases, Breast Neoplasms, Estrogen Receptor Negative, +20 more
Locations
  • Nebraska Medicine-Bellevue Bellevue, Nebraska, United States
  • CHI Health Saint Francis Grand Island, Nebraska, United States
  • Nebraska Medicine-Village Pointe Cancer Center Omaha, Nebraska, United States
  • University of Nebraska Medical Center Omaha, Nebraska, United States
View Trial Details
Completed

Paclitaxel, Nab-paclitaxel, or Ixabepilone With or Without Bevacizumab in Treating Patients With Stage IIIC or Stage IV Breast Cancer

NCT00785291

Conditions
Breast Diseases, Breast Neoplasms, Estrogen Receptor Negative, +12 more
Locations
  • Mayo Clinic in Arizona Scottsdale, Arizona, United States
  • Sparks Regional Medical Center Fort Smith, Arkansas, United States
  • Mercy Hospital Fort Smith Fort Smith, Arkansas, United States
  • NEA Baptist Memorial Hospital Jonesboro, Arkansas, United States
View all 704 locations
View Trial Details
Completed

Palbociclib and Letrozole or Fulvestrant in Treating Patients With Estrogen Receptor Positive, HER2 Negative Metastatic Breast Cancer

NCT03633331

Conditions
Estrogen Receptor-positive Breast Cancer, HER2/Neu Negative, Stage IV Breast Cancer AJCC v6 and v7
Locations
  • Anchorage Associates in Radiation Medicine Anchorage, Alaska, United States
  • Anchorage Radiation Therapy Center Anchorage, Alaska, United States
  • Alaska Breast Care and Surgery LLC Anchorage, Alaska, United States
  • Alaska Oncology and Hematology LLC Anchorage, Alaska, United States
View all 447 locations
View Trial Details
Completed

Alisertib With or Without Fulvestrant in Treating Patients With Locally Advanced or Metastatic, Endocrine-Resistant Breast Cancer

NCT02860000

Conditions
Breast Diseases, Breast Neoplasms, Estrogen Receptor Status, +12 more
Locations
  • Georgetown University Medical Center Washington D.C., District of Columbia, United States
  • Dana-Farber Cancer Institute Boston, Massachusetts, United States
  • University of Michigan Ann Arbor, Michigan, United States
  • Mayo Clinic Rochester, Minnesota, United States
View Trial Details
Completed

Endocrine Therapy Fulvestrant & Palbociclib or Aromatase Inhibitor Therapy in Treating Older Patients With Hormone Responsive Breast Cancer That Cannot Be Removed by Surgery

NCT02760030

Conditions
Breast Diseases, Breast Neoplasms, Estrogen Receptor and/or Progesterone Receptor Positive, +12 more
Locations
  • St. Elizabeth Healthcare Edgewood, Kentucky, United States
  • Case Western University Cleveland, Ohio, United States
  • Ohio State University Comprehensive Cancer Center Columbus, Ohio, United States
View Trial Details

Related conditions